The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

A large prospective cohort study in Germany found no statistically significant increase in major birth defects following ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

A new COVID variant - NB 1.8.1 - is creeping across California; here are the symptoms to watch for, and vaccinations you'll ...

In a crucial development, the FDA has approved Moderna's new COVID-19 vaccine designed specifically for high-risk Americans.

Robert F. Kennedy, Jr., the new Secretary of the U.S. Department of Health and Human Services (HHS), recently announced that ...

The Trump administration is waging war against mRNA vaccines despite President Donald Trump having called them the “gold standard” when his admin rolled out the COVID shots […] ...

A vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...